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Summary
Objective: The infrapatellar fat pad (IPFP) has been identiﬁed as a source of anterior knee pain. Fibrosis and marked inﬂammatory inﬁltrate in
the IPFP of patients with arthritis of the knee and reduction in pain post knee replacement in patients following resection of the IPFP have been
observed. We have investigated changes in the IPFP of rats undergoing the monoiodoacetate (MIA) model of degenerative joint disease,
a model that exhibits some histopathological similarities to osteoarthritis (OA).
Methods: Rats were injected intra-articularly with MIA and the development of weight bearing asymmetry was followed for 21 days as com-
pared to vehicle-injected animals. In addition, IPFPs were removed from both ipsilateral and contralateral joints. Both inﬂammatory inﬁltrate
and histopathological changes were analysed.
Results: MIA injection caused marked weight bearing asymmetry. Ipsilateral IPFP wet weights were signiﬁcantly increased on days 1 and 3 in
MIA-treated animals. MIA treatment also resulted in signiﬁcant increases in IPFP total white blood cells and monocytes on days 1, 3, and 7
and neutrophils on days 1 and 3. This was supported by histopathological ﬁndings at early time points which progressed to adipocyte necrosis,
IPFP ﬁbrosis, patellar cartilage and subchondral bone necrosis with synovial hyperplasia at later timepoints.
Conclusions: The current study clearly demonstrated that marked inﬂammatory changes in the IPFP occur during the early stage of the MIA
model of OA which may contribute to the pain observed at this early stage. The role of the IPFP in later stages of the model needs to be further
explored.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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A recent hypothesis proposes that osteoarthritis (OA) may
be the result of a systemic metabolic disorder1, as is re-
ﬂected in the correlation between OA and obesity and in
the hypothesis that OA can result from a dysregulation of
lipid homeostasis1e5. Adipose tissue is regarded as an ac-
tive endocrine organ, serving a role in several physiological
processes such as appetite modulation, insulin sensitivity,
bone metabolism and other endocrine functions6. Adipo-
cytes can secrete proinﬂammatory cytokines and growth
factors7,8 and are therefore believed to contribute to tissue
inﬂammation and immunity.
Adipose tissue in the joint has been suggested to play
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805but the local biological function of articular adipose tissue
has still to be investigated. The infrapatellar fat pad
(IPFP) is one of many fat pads in the body. These fatty
structures within joints facilitate distribution of synovial ﬂuid
and may act to absorb forces generated through the joint.
The IPFP is located inferiorly of the patella and posteriorly
of the patella tendon (or patella ligament). It lies between
the patella, femur, meniscus and tibia and completely ﬁlls
the potential space between these structures. The IPFP is
highly vascularised and innervated, with its primary blood
supply originating from the synovial membrane9 and its
sensory nerves originating from the posterior articular
branch of the posterior tibial nerve10,11. Little is known
about the IPFP changes in OA, but in generalised anterior
knee pain or Hoffa’s disease the IPFP is found to be af-
fected by inﬂammation, hypertrophy, and ﬁbrosis12,13. A re-
cent study by Macule et al. of 70 patients suffering from OA
undergoing total knee arthroplasty showed that more pa-
tients who underwent fat pad resection at the time of joint
replacement described no pain (using a simple visual ana-
logue scale assessment) during a 6-month follow-up indi-
cating that the IPFP is a potential source of pain even
after joint replacement14. Nerves innervating the IPFP
have been found to be Substance P positive, indicating
that they are peptidergic C-ﬁbres15 and these nerves are
806 K. M. Clements et al.: Infrapatellar fat pad in MIA modelincreased in the IPFP of patients with chronic anterior knee
pain16.
Numerous animal models that mimic aspects of human
OA have been developed to study the pathophysiology of
the disease and to evaluate therapeutic modalities. Injec-
tion of monoiodoacetate (MIA) into articular joints is one
that has been extensively characterised as a model of
degenerative joint disease17,18. MIA inhibits glyceralde-
hyde-3-phosphate dehydrogenase activity in chondrocytes
within the articular cartilage resulting in disruption of glycol-
ysis and cell death. The loss of chondrocytes resembles
the histological and morphological changes to arthritic ar-
ticular cartilage. It produces a rapid development of joint
damage and short time to appearance of classical disease
features, including pain and changes in bone morphology.
The model exhibits two distinct phases of pharmacological
sensitivity to hind limb weight bearing asymmetry, with an
early cyclo-oxygenase (COX) sensitive phase and a later
COX insensitive phase, which shows evidence of nerve
injury17.
The aims of the current study were to characterise the
temporal structural and cellular changes in the IPFP in the
MIA model of OA pain.MethodsANIMALSAll experimental procedures were conducted in accordance with the UK
Home Ofﬁce (Animals In Scientiﬁc Procedures Act 1986) and following local
ethical review. Male Wistar rats (Harlan, UK), 185e205 g, were group
housed under a 12 h/12 h light/dark cycle with access to a standard pellet
diet and water ad libitum. Prior to initiation of studies animals were rando-
mised and assigned to treatment groups. A total of 150 rats were used for
the study, 18 per timepoint for behavioural and cellular analysis and 12
per timepoint for histopathological assessment (Fig. 1).MIA INJECTIONAnimals were prepared for intra-articular injection of MIA (Sigma, UK) by
brief anaesthesia with isoﬂurane (3% in O2 at 1.5 l/min). Intra-articular injec-
tion of 1 mg MIA in 20 ml 0.9% sterile saline (n ¼ 6 per timepoint) or vehicle
control (n ¼ 6 per timepoint; 20 ml, 0.9% sterile saline alone) was adminis-
tered through the infrapatellar ligament into the joint space of the right
knee via a 30G needle. An additional n ¼ 6 animals per timepoint remained
un-injected (na€ıve). The dose of MIA chosen was determined based on pre-
vious literature17.n = 150 Male Wis
Behavioural Assessment 
MIA (n = 6) Saline (n = 6) Naive (n = 6)
n=18 per timepoint 
Days 1, 3, 7, 14 and 21
n=90 animals total
Cellular Assessment carried out on animals from
days 1-14 post-MIA 
M
Fig. 1. Flow-diagram illustrating stuBEHAVIOURAL TESTINGWeight re-distribution, as measured by an incapacitance meter (Linton In-
struments, UK), is assumed to be a behavioural measure of musculoskeletal
discomfort18,19. Brieﬂy, animals were placed into a Perspex chamber over ip-
silateral and contralateral hind limb force transducer panels and given ade-
quate time to settle. Once settled, with both hind paws on the appropriate
panel, a reading was taken. A digital readout of the mean weight exerted
on each panel, over a period of 5 s, was taken for each animal and measured
in grams. In the current studies, all animals were habituated to the apparatus
prior to initiation of the experimental period.
Weight bearing measurements were taken immediately before admin-
istration of intra-articular MIA or vehicle control (20 ml, 0.9% sterile sa-
line) and at days 1, 3, 7, 14 and 21 by averaging over three separate
readings within a given test session. Data were analysed as the percent-
age difference in weight distribution (ipsilateral/contralateral) 100. A
value of 100% represented equal weight distribution across ipsilateral
and contralateral hind limbs. Data are presented as arithmetic mean -
 standard error of the mean (S.E.M.). Signiﬁcant changes in weight bear-
ing asymmetry were assessed on raw data using two-way analysis of
variance (ANOVA) followed by Bonferroni’s post-hoc test against time-
matched controls. A P value of <0.05 was considered to be statistically
signiﬁcant.TISSUE COLLECTION AND PREPARATION e IPFP CELLULAR
INFILTRATE ANALYSISFollowing weight bearing assessments on days 1, 3, 7, and 14, animals
from both treatment groups were humanely killed and IPFP’s were removed
from the ipsilateral and contralateral knees. Due to the normalisation of the
cellular response to MIA injection by day 14, for ethical reasons this arm
of the study was terminated at day 14 rather than day 21. Brieﬂy, the infra-
patellar ligament was cut at the femoral head and dissected, but not de-
tached from IPFP, until the joint capsule was exposed. The IPFP was then
dissected away from the tibia and removed from the ligament and the wet
weight subsequently recorded. Phosphate buffered saline (PBS) containing
100 U/ml Penicillin, 10 mg/ml Streptomycin, 25 mg/ml Amphotericin (P/S/A)
(Dulbecco’s PBSA, Sigma, UK) was used as a storage medium until subse-
quent digestion.
A digestion solution was prepared containing 4% bovine serum albumin
(BSA), and 0.6 mg/ml collagenase from Clostridium histolyticum
(SigmaeAldrich). Each individual sample was immersed in digestion solu-
tion and continually agitated at 37C for 1.5 h. The digested IPFPs were ﬁl-
tered (100 mm Nylon Filter, BD Falcon) and centrifuged at 1400 rpm for
5 min. The supernatant was removed and 200 ml of medium 199 (Gibco,
Invitrogen, UK)þP/S/A at 37C was added to the cell-containing pellet
and re-suspended.DIFFERENTIAL WHITE BLOOD CELL (WBC) COUNT BY
SYSMEX XT-VETDifferential WBC counts, from each IPFP, were quantiﬁed using the
Sysmex XT-VET, an automated differential cell analyser. Monocytes/tar Rats
Histopathological Assessment
n=12 per timepoint 
IA (n = 4) Saline (n = 4) Naive (n = 4)
Days 1, 3, 7, 14 and 21
n=60 animals total
dy design and animal usage.
807Osteoarthritis and Cartilage Vol. 17, No. 6macrophages, neutrophils, lymphocytes, basophils and eosinophils were
identiﬁed using ﬂuorescence ﬂow cytometry technology. Data are presented
as arithmetic mean  S.E.M. Signiﬁcant changes in IPFP wet weights and cell
counts were assessed on raw data using two-way ANOVA followed by Bon-
ferroni’s post-hoc test against time-matched and contralateral controls. A
P value of <0.05 was set as the level of statistical signiﬁcance.
Each IPFP cell suspension sample was also cytocentrifuged for histolog-
ical veriﬁcation of the cellular content (Shandon cytospin 4, Thermo Electron,
UK). Geimsa stain (Fisher Co.) was applied post-centrifugation for cell type
identiﬁcation.TISSUE COLLECTION AND PREPARATION e IPFP
HISTOPATHOLOGY AND IMMUNOHISTOCHEMISTRYFig. 2. Weight bearing asymmetry proﬁle over a 21-day time
course, measured at days 1, 3, 7, 14 and 21 post-MIA (or vehicle)
injection (n¼ 6 per group per timepoint). Intra-articular MIA injection
into the rat knee joint produced a signiﬁcant decrease in ipsilateral
weight bearing with a biphasic pattern compared to vehicle and
na€ıve animals. Signiﬁcance was determined using two-way AN-
OVA, post-hoc Bonferroni’s, ***P< 0.001. Data are presented as
means S.E.M.Following weight bearing assessments on days 1, 3, 7, 14 and 21, a sep-
arate set of animals treated with either MIA (n ¼ 4 per timepoint) or vehicle
(n ¼ 4 per timepoint) was terminally anaesthetised and perfused transcar-
dially with 200 ml heparinized saline (10 IU/ml) (CP Pharmaceuticals, UK)
and 250 ml ice-cold fresh paraformaldehyde (PFA; 4%) (Sigma, UK) in
0.1 M PBS. A separate group of n ¼ 4 animals per timepoint remained un-
injected (na€ıve) and was terminated in the same way.
For histopathological assessment, the infrapatellar ligaments were cut at
the femoral head, dissected and freed but not detached from IPFP, until the
joint capsule was exposed. Excess muscle and connective tissue were re-
moved and the infrapatellar ligament along with the patella and IPFP were
removed as one. All samples were ﬁxed for 24e48 h in 10% neutral buffered
formalin and subsequently decalciﬁed for 36 h (decalciﬁcation solution
changed every 2 h for ﬁrst 12 h) in a Surgipath Decalciﬁer II (Surgipath Eu-
rope Ltd). Each individual sample was orientated in cassettes for prepara-
tion by standard histological techniques of wax blocks for subsequent
sectioning. Each was sectioned in the sagittal or parasagittal plane and
3e5 mm thick sections stained with haematoxylin and eosin for histopatho-
logical assessment.LIGHT NEUROFILAMENT PROTEIN (LNP)
IMMUNOHISTOCHEMISTRYIn order to study innervation in the fat pad we used an antibody against
LNP as a general nerve stain. Immunohistochemistry was performed on
4 mm formalin-ﬁxed, parafﬁn wax-embedded sections which were dewaxed
in xylene and rehydrated through graded alcohols to water. Antigen retrieval
was performed by microwave at 110C for 2 min in citrate buffer (pH 6) using
the Milestone RHS2 microwave (with pressure vessel) followed by washing
of sections in water before being placed onto a Labvision Immunostainer
where the remainder of the immunohistochemical staining was performed.
Sections were ﬁrst washed in Tris buffered saline with 0.05% Tween
(TBST) followed by blockade of endogenous peroxidase with 3% hydrogen
peroxide (diluted in TBST) for 10 min. Another TBST wash was followed
by incubation of sections for 20 min with a normal goat serum block
(DakoX0907) diluted 1:20 in TBST, followed by application of primary anti-
body [rabbit poly anti-neuroﬁlament] (ab9035, Abcam) at a dilution of
1:1000 for 60 min at room temperature. The detection system was rabbit
Envision-HRP kit (Dako, K4011) applied for 30 min and visualized by 3,3-
diaminobenzidine (DAB, Dako).ResultsWEIGHT BEARING ASSESSMENTIntra-articular injection of MIA (n ¼ 6) signiﬁcantly de-
creased ipsilateral weight bearing at all timepoints as com-
pared to vehicle controls (n ¼ 6) (Fig. 2). As previously
reported17, this response appeared biphasic. Displacement
of weight bearing to the contralateral limb peaked between
days 1and 3, moderating to a stable plateau of asymmetry
for the remaining period of study.IPFP WET WEIGHTMIA injection produced a signiﬁcant, greater than two-
fold, increase in ipsilateral IPFP wet weight [Fig. 3(A)] com-
pared to vehicle-injected animals on day 1 (158% increase,
P < 0.001) and day 3 (142% increase, P < 0.001) but not at
any later timepoints. No changes were observed in contra-
lateral knee joints (data not shown).INFLAMMATORY CELL INFILTRATEOn day 1 post-MIA injection there was a signiﬁcant in-
crease in WBC in the ipsilateral IPFP, in particular, mono-
cytes, neutrophils and basophils (Table I). Interestingly,
a two-fold increase in monocytes (P < 0.05, data not
shown) was also seen in the contralateral IPFP of MIA-in-
jected animals when compared with vehicle-injected ani-
mals. This was not observed with other cell types or at
any further timepoints.
Cellularity of the ipsilateral IPFP peaked at day 3 in all cell
types studied and then declined over the remaining period
(days 7 and 14). Fold changes were greatest in monocyte,
neutrophil and basophils when comparing MIA animals to
vehicles. Whilst statistical signiﬁcance was lost over the re-
maining period of study, at day 14 these cell types still ex-
hibited elevated cell counts in MIA-treated animals vs
vehicle. Furthermore, the temporal proﬁle of these cells ap-
pears to be well matched to the weight bearing asymmetry
proﬁle.
The MIA speciﬁc nature of the response was further con-
ﬁrmed by the fact that no signiﬁcant changes in wet weight
and inﬂammatory cell inﬁltrate were noted in na€ıve animals
over time (data not shown).CYTOSPIN CONSOLIDATIONThe differential WBC count data were conﬁrmed by histo-
logical analysis of the samples after staining with Giemsa.
Intra-articular MIA injection produced marked increases in
total WBC count seen on the cytospin slides of the ipsilat-
eral MIA-treated animals as compared to contralateral fat
pads and vehicle-treated animals, particularly in monocyte
and neutrophil cell counts (Fig. 4).HISTOPATHOLOGYAll knee joints, at all timepoints, that were un-injected
(na€ıve) or those that were injected with vehicle only, or
the contralateral joints from MIA-injected knees, showed
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Fig. 3. Ipsilateral fat pad wet weights and total white blood cell (TWBC) counts measured over a 14-day time course, at days 1, 3, 7, and 14 in
MIA-injected (grey bars) and vehicle animals (white bars) (n¼ 6 per group per timepoint). Intra-articular MIA injection into the rat knee joint
produced a signiﬁcant increase in TWBC and monocyte count at days 1, 3 and 7 and neutrophil count at days 1 and 3. Signiﬁcance was de-
termined using two-way ANOVA, post-hoc Bonferroni’s, *P< 0.05, **P< 0.01, ***P< 0.001. Data are presented as means S.E.M.
808 K. M. Clements et al.: Infrapatellar fat pad in MIA modelneither tissue necrosis, inﬂammatory cell inﬁltration nor
ﬁbrosis of the synovial membrane, fat pad or adjacent
tissues [Fig. 5(A)].
Injection of MIA induced substantial changes in numerous
knee structures at different times post dose. On day 1, syno-
vial membrane and subjacent connective tissue necrosis in
conjunction with substantial acute inﬂammatory cell inﬁltra-
tion and oedema into fat pad and adjacent connective tissues
were apparent [Fig. 5(B)]. Fat pad adipocyte necrosis was
a common feature at this time [Fig. 5(C)]. Necrotic tissue de-
bris, some of which showed early mineralisation, lay close to
and adhered to the damaged synovial membrane. Patellar
cartilage on the joint luminal aspect was substantially, focally
necrotic. Minimal synovial membrane hyperplasia was also
an occasional feature at this time.
On day 7, mild synovial membrane hyperplasia and con-
siderable sub-synovial ﬁbroplasia were common features,Table I
Fold increase in cell count in the IPFP of MIA compared with vehi-
cle-treated animals at days 1, 3, 7 and 14 post-intra-articular MIA
injection as measured using Sysmex XT-VET
Day 1 Day 3 Day 7 Day 14
TWBC 12.2 26.5 6.5 3.5
Monocyte 17.2 37.5 8.5 4.1
Neutrophil 7.9 16.5 2.9 2.9
Lymphocyte 0 2.9 0 0.3
Basophil 6.7 43.3 3.9 5.7
Eosinophil 2.8 3.5 1.9 0and often found in association with more extensive patellar
fat pad adipocyte loss and granulation tissue. Adjacent pa-
tellar cartilage necrosis and chondroplasia were also asso-
ciated with subjacent bone necrosis [Fig. 5(D)].
On day 14, some necrotic debris remained within the joint
cavity and was adherent to damaged synovial membrane
often with associated mild synovial hyperplasia. Prominent
loss of patellar fat pad adipocytes was noted in conjunction
with further ﬁbroplasia and now, more extensive ﬁbrosis
[Fig. 5(E)]. The pathological features in patellar bone and
cartilage noted at earlier timepoints were also present and
appeared to be more extensive in distribution and severity.
On day 21, the features described above remained pres-
ent but to a more advanced degree. Patellar fat pad adipo-
cyte loss did not appear to have progressed further, but the
intercellular separation of adipocytes by ﬁbrous tissue had
increased substantially. Additionally, the prominent sub-sy-
novial ﬁbroplasia and ﬁbrosis were more extensive and con-
tained minute fragments of bone lying subjacent to the
thickened, hyperplastic synovial membrane. Patellar chon-
dral fragmentation and disintegration of necrotic subchon-
dral bone in association with ﬁbrocartilage proliferation
was a signiﬁcant feature at this time.
No change in distribution of LNP staining was noted in
any treatment group or time [see Fig. 5(A), insert].
Discussion
The present study clearly demonstrates that marked
changes occur in the IPFP in the MIA model of OA pain.
Fig. 4. Giemsa staining of the digested fat pad at day 1: post-injection, ipsilateral (A) and contralateral (B) of vehicle-treated animal and ipsi-
lateral (C) and contralateral (D) of MIA-treated animal. Intra-articular MIA injection produced marked increases in TWBC count in ipsilateral
MIA-treated animals (C) compared to ipsilateral legs of vehicle-treated animals (A) at day 1, particularly in monocyte (arrow) and neutrophil
(arrowhead) cell counts, conﬁrming the Sysmex differential cell count results. A smaller increase was seen in the contralateral MIA monocyte
cell count (D) compared to contralateral legs of vehicle-treated animals (C) at day 1, conﬁrming the Sysmex data for day 1 post-injection. Sim-
ilarly, the Sysmex results for days 3, day 7, and day 14 were conﬁrmed.
809Osteoarthritis and Cartilage Vol. 17, No. 6These changes are characterised by increased wet weight
and acute inﬂammatory cell inﬁltrate at the earlier stage of
the disease which progress to synovial hyperplasia, ﬁbrosis
and patellar cartilage and bone necrosis in the later stages.
The general absence of increased wet weight and inﬂamma-
tory cell inﬁltrate in the contralateral IPFP and in vehicle con-
trol animals conﬁrms the local and MIA speciﬁc nature of this
cellular inﬁltration and excludes the possibility that the effects
are caused by a general response to injection. This was fur-
ther conﬁrmed by comparison with na€ıve animal data.
The changes in differential WBC counts observed follow
the sequence and general time course of inﬂammatory
cell recruitment at sites of tissue damage as previously de-
scribed20. Monocyte cell counts, which normally account for
only 3e8% of the TWBC in the blood, showed the biggest
response to MIA injection in this study. There was also
a two-fold increase in monocytes contralaterally on day 1.
This contralateral response on day 1 might be indicative
of a systemic response to MIA or the result of altered weight
bearing on the limb causing contralateral joint response21.
Neutrophils and monocytes/macrophages are generally
the predominant cells at sites of inﬂammation but it is some-
what surprising that the observed increase in monocyte
number was much more profound than the increases in
neutrophil numbers (up to 37-fold vs up to six-fold), al-
though we might have missed an earlier neutrophil peak
by not taking samples prior to 24 h post-MIA injection.Neutrophils have been extensively studied for their potential
role in cartilage degradation. It has been reported that neu-
trophil collagenase matrix metalloprotease-8 (MMP-8) in-
hibits alpha 2 macroglobulin22, an endogenous inhibitor of
aggrecanases involved in cartilage degradation23. Further-
more, neutrophils will also release cytokines such as IL1,
IL8 and transforming growth factor beta 1 (TGFb1). Whilst
the relative amounts of cytokine release from neutrophils
are low, their high number present in a relatively restricted
tissue may argue in favour of a local and early neutrophil
driven inﬂammation, which may also drive adipocyte
necrosis.
It is conceivable that MIA injection enhances the produc-
tion of speciﬁc proteases and chemokines that mediate the
migration of monocytes to the site of inﬂammation, such as
Cathepsin G and monocyte chemoattractant proteins24,25.
Adipose tissue has previously been reported to secrete
monocyte chemotactic protein-1 (MCP-1)26. In addition, ad-
ipocyte necrosis itself may lead to increased inﬂammatory
cell inﬁltrate into the IPFP.
It is questionable to what extent the changes in low basal
cell counts are biologically relevant although it should be
noted that these changes in percentage terms are relatively
large. The fact that consistent data are obtained implies that
the effects observed are meaningful and these cell count
changes have a functional role to play in the ipsilateral
IPFP post-MIA injection. The extremely low lymphocyte
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Fig. 5. (A) Control: contralateral knee injected with saline, 7 days. Synovium and fat pad are normal. Insert: LNP immunohistochemistry show-
ing a transversely sectioned, small perivascular nerve containing numerous positively stained axons. Note that no increase in number of fat
pad nerves was noted at any time following MIA injection. (B) MIA-injected knee joint: fat pad, 1 day. Note the necrotic debris in the joint cavity
(arrow) and adherent to the underlying (arrow). Some synovial proliferation present but with substantial acute inﬂammatory cell inﬁltration (ar-
rowheads) into adjacent fat pad lying around and between adipocytes. (C) MIA-injected knee joint: fat pad, 1 day. Diffuse necrosis of synovial
membrane (arrow) and subjacent fat pad adipocytes (arrowhead) with multifocal haemorrhage (H) and minimal acute inﬂammatory cell inﬁl-
tration. (D) MIA-injected knee joint: fat pad, 7 days. Necrosis of patellar cartilage (*) with fragmentation of patellar bone (B) associated with
chondroplasia (C) and bone resorption with activated multinucleated osteoclasts (arrows). (E) MIA-injected knee joint: fat pad, 21 days.
Extensive synovial proliferation (SP) and sub-synovial ﬁbrosis (F) with marked loss of adipocytes. Note the extensive vascular network
(arrowheads) in the sub-synovial tissue.
810 K. M. Clements et al.: Infrapatellar fat pad in MIA modelnumbers seem to point to a negligible biological effect of
these leukocytes within the IPFP in the MIA model, espe-
cially since they are normally present in greater numbers
systemically (2.2  109/l blood), as previously the relative
percentage change in this population may represent func-
tional signiﬁcance. These ﬁndings are not in accordance
with other studies that have shown marked increases in
lymphocyte numbers in the MIA model in the synovium18.This perhaps indicates a role for these cell types in synovitis
in MIA but not in the changes observed in the IPFP.
Eosinophils and basophils are, in contrast, present in
small numbers under normal conditions in the blood (0e7
and 0e4.8  107/l blood, respectively). Therefore, the up
to seven-fold increases in this study more likely represent
an effect of biological signiﬁcance. The exact role that these
cells play in the MIA model is unclear but may relate to an
811Osteoarthritis and Cartilage Vol. 17, No. 6increased histamine release that has been reported in other
rodent models of monoarthritis. Regulated secretion by ba-
sophils can be induced by non-immunological agonists.
Whilst there are functional differences between species
and tissues, basic biomolecules such as analogues of Sub-
stance P are capable of activating rat basophils and releas-
ing histamine. This might support a role for peptidergic
neurogenic inﬂammation in the IPFP via Substance
P release.
The histopathological changes observed in the fat pad re-
ﬂect the inﬂammatory cell changes seen temporally, with
evidence of an acute inﬂammatory response initially, pro-
gressing to a more chronic inﬂammation. This progression
involved patellar cartilage and bone necrosis, adipocyte ne-
crosis and IPFP ﬁbrosis. Fibrosis was a feature of fat pad
pathology in this model which has also recently been re-
ported in the plantar fat pad27 as well as in the IPFP28. It
is plausible that adipoctye necrosis renders the IPFP less
able to absorb the forces, physiological as well as patholog-
ical, placed through the joint promoting and perpetuating
joint destruction.
The data presented here conﬁrm previously reported
changes in articular structures such as cartilage, synovium
and subchondral bone and present for the ﬁrst time evi-
dence of signiﬁcant changes to the IPFP in the MIA model.
These ﬁndings are particularly relevant given recent clinical
data29 showing that changes in the IPFP most closely cor-
relate to pain in OA patients with synovitis. Our ﬁndings
highlight that the contribution of the IPFP to joint pain may
initially result from inﬂammatory cell inﬁltration, leading to
the release of numerous inﬂammatory mediators, possibly
acting to alter the sensitivity of sensory nerve afferent termi-
nals. In addition to this, subsequent ﬁbrosis of the IPFP is
likely to contribute to joint pain at the later stage of the
MIA model (subsequent to a decrease in the initial inﬂam-
matory response). Fibrotic scars in the IPFP have been de-
scribed in numerous clinical reports30,31 and indeed have
even been related to pain14. Perhaps it is surprising that
there were no changes in LNP staining in MIA animals as
compared to vehicle-treated controls, given the literature
evidence for increased Substance P ﬁbre staining in OA
knees. This may, however, be due to a dilution of signal
by staining all neurones using LNP in the present study,
when any neuronal changes may be limited to a subset of
peptidergic C-ﬁbres. In conclusion, the present study illus-
trates marked changes in the IPFP in the MIA model which
may have translational salience to pain experienced by
some OA patients. It should be noted, however, that we
did not analyse other anatomical subregions (e.g., inﬂam-
mation in the intercondylar notch or perimeniscal subchon-
dral bony alterations) which may also contribute to the
clinical ﬁndings observed in the animals.Conﬂict of interest
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